Anthropic publishes early drug development results from using Claude
AIMade by AIWritten by AI (Claude) from the source below. Check anything important against the source.How it's made
Anthropic publishes early drug development results from using Claude — it put out what six partner companies got from using Claude and Claude Code for design, optimization and regulatory document review, together with partner technical reports
Why it matters
All the figures come from the company and its partners, with no independent check. Generate Biomedicines said one CAR T design proposed by 6 researchers was about 70% shorter than the standard and produced about 10 times more receptor in experiments, and Divergence Labs said it generated about 35,000 antibody designs in about a month and found 3 that bind IgE and 20 that pull it off. BigHat Biosciences said it made about 1,010 variants in about 10 weeks and that the best candidate bound more than 10 times more strongly, and Enveda wrote that in a 1,061-page document it caught all 11 items a person had found and found 7 more, cutting review time from more than 25 hours to under 3 hours, a reduction of 89%. Anthropic's own program Mithril Medicine took a muscle-disease candidate as far as mouse results in under 18 months and raised the possibility of human trials by the end of 2028, but that is a projection, not a result
Source — Primary sources first; secondary reports are labelled “Press”
Officialanthropic.comhttps://www.anthropic.com/research/early-progress-drug-developmentAdded in Week 44, 2026 · See that week
On the map — ⑭ Physical World line
- Previous stopClaude agents find ART, an undescribed enzyme system, in bacteriophages
- This recordAnthropic publishes early drug development results from using Claude
- Next stopAnthropic expands AI for Science to foundations and research institutions